Evercore ISI slashes price target on Vaxxinity Inc. [VAXX] – find out why.

Vaxxinity Inc. [NASDAQ: VAXX] price plunged by -9.16 percent to reach at -$0.24. The company report on November 10, 2022 that Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients.

VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates.

A sum of 8587669 shares traded at recent session while its average daily volume was at 188.71K shares. Vaxxinity Inc. shares reached a high of $3.95 and dropped to a low of $2.35 until finishing in the latest session at $2.38.

The one-year VAXX stock forecast points to a potential upside of 82.37. The average equity rating for VAXX stock is currently 1.70, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Vaxxinity Inc. [VAXX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VAXX shares is $13.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VAXX stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Evercore ISI have made an estimate for Vaxxinity Inc. shares, keeping their opinion on the stock as In-line, with their previous recommendation back on April 27, 2022.

The Average True Range (ATR) for Vaxxinity Inc. is set at 0.31 The Price to Book ratio for the last quarter was 3.72, with the Price to Cash per share for the same quarter was set at 0.80.

VAXX Stock Performance Analysis:

Vaxxinity Inc. [VAXX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 36.78. With this latest performance, VAXX shares gained by 70.00% in over the last four-week period, additionally sinking by -50.31% over the last 6 months – not to mention a drop of -78.24% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VAXX stock in for the last two-week period is set at 68.61, with the RSI for the last a single of trading hit 71.44, and the three-weeks RSI is set at 64.69 for Vaxxinity Inc. [VAXX]. The present Moving Average for the last 50 days of trading for this stock 1.74, while it was recorded at 2.19 for the last single week of trading, and 2.90 for the last 200 days.

Insight into Vaxxinity Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Vaxxinity Inc. [VAXX] shares currently have an operating margin of -189507.58 and a Gross Margin at -4504.55. Vaxxinity Inc.’s Net Margin is presently recorded at -207840.91.

Return on Equity for this stock declined to -264.51, with Return on Assets sitting at -126.54.

Vaxxinity Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.30.

Vaxxinity Inc. [VAXX] Insider Position Details

There are presently around $63 million, or 23.40% of VAXX stock, in the hands of institutional investors. The top three institutional holders of VAXX stocks are: PRIME MOVERS LAB LLC with ownership of 17,603,276, which is approximately -1.373% of the company’s market cap and around 47.00% of the total institutional ownership; BANK OF AMERICA CORP /DE/, holding 3,203,220 shares of the stock with an approximate value of $7.62 million in VAXX stocks shares; and VANGUARD GROUP INC, currently with $5.26 million in VAXX stock with ownership of nearly 44.538% of the company’s market capitalization.

Positions in Vaxxinity Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 12 institutional holders increased their position in Vaxxinity Inc. [NASDAQ:VAXX] by around 1,694,329 shares. Additionally, 17 investors decreased positions by around 1,548,548 shares, while 9 investors held positions by with 23,026,616 shares. The mentioned changes placed institutional holdings at 26,269,493 shares, according to the latest SEC report filing. VAXX stock had 9 new institutional investments in for a total of 741,005 shares, while 8 institutional investors sold positions of 433,285 shares during the same period.


Please enter your comment!
Please enter your name here